Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BRKR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BRKR and 80,000+ other tickers.
See exactly how BRKR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BRKR and 80,000+ other tickers.
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature…
BREMEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search.
BRKR's rally is fueled by BSI NANO growth, AI-driven metrology demand and gains in preclinical imaging despite tariff pressures.
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
On June 15, 2026, Bruker Corp (BRKR) shares rose 4.4% to a current price of $56.63. The stock has shown remarkable performance within the past year, with a 48.7
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript